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Background: Beneficial mutations play an essential role in bacterial adaptation, yet little is known about their
fitness effects across genetic backgrounds and environments. One prominent example of bacterial adaptation is
antibiotic resistance. Until recently, the paradigm has been that antibiotic resistance is selected by the presence of
antibiotics because resistant mutations confer fitness costs in antibiotic free environments. In this study we show
that it is not always the case, documenting the selection and fixation of resistant mutations in populations of
Escherichia coli B that had never been exposed to antibiotics but instead evolved for 2000 generations at high
temperature (42.2°C).
Results: We found parallel mutations within the rpoB gene encoding the beta subunit of RNA polymerase. These
amino acid substitutions conferred different levels of rifampicin resistance. The resistant mutations typically
appeared, and were fixed, early in the evolution experiment. We confirmed the high advantage of these mutations
at 42.2°C in glucose-limited medium. However, the rpoB mutations had different fitness effects across three genetic
backgrounds and six environments.
Conclusions: We describe resistance mutations that are not necessarily costly in the absence of antibiotics or
compensatory mutations but are highly beneficial at high temperature and low glucose. Their fitness effects depend
on the environment and the genetic background, providing glimpses into the prevalence of epistasis and pleiotropy.
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Mutations supply the genetic variation for adaptation,
but their success depends on the selective coefficient (s),
which influences both the probability of fixation of a
mutation and its frequency trajectory [1]. Highly advan-
tageous mutations have a higher probability of escaping
loss by genetic drift and are also expected to reach high
frequency more rapidly than mutations of smaller bene-
ficial effect [2]. The selection coefficient is a function
not only of the mutation itself but also of the genetic
background; the effect of a mutation may change in
amplitude or even in sign (shifting, for example, from* Correspondence: olivier.tenaillon@inserm.fr
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distribution, and reproduction in any mediumbeneficial to neutral or even deleterious) across genetic
backgrounds due to epistatic effects [3-6]. Epistatic
interactions may also limit the emergence and propagation
of further beneficial mutations, thereby affecting long-
term chances of survival [7]. Finally, s may differ across
environments (e.g. [8-10]), including the possibility of
genotype-by-environment (GXE) interactions. These dif-
ferential effects may have a profound influence on the
pattern of adaptation, because they may prevent a muta-
tion from fixing across heterogeneous environments, which
in turn leads to niche (or ecological) specialization [11].
Antibiotic resistance is a particularly important class
of beneficial mutation, both because of its potential
implications for public health [12] and because resist-
ance is easily studied in the laboratory, particularly in
model systems like Escherichia coli [13,14]. Genetic resist-
ance to antibiotics can result either from sequential accu-
mulation of multiple beneficial mutations - e.g. resistanceMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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substitution - e.g. resistance to rifamycins [16]. This last
mutational type is typically highly advantageous in the
presence of antibiotics, leading to rapid fixation, often
within hundreds of generations [17].
Despite their advantage in the presence of antibiotics,
resistance mutations are usually deleterious in the absence
of antibiotics, because they often modify vital cellular
functions and are highly pleiotropic. For example, amino
acid substitutions in the β subunit of the RNA polymerase
(RNAP) that produce resistance to rifampicin [18] dimin-
ish the transcription efficiency of RNAP and often entail
a fitness cost in the absence of rifampicin [19,20]. How-
ever, antibiotic resistance may not always be associated
with fitness costs; resistance mutations sometimes ap-
pear to be neutral or even beneficial in the absence of
antibiotics [10,21,22], but for these cases the possibility
of secondary advantageous mutations have not been
precluded. Costly resistance mutations may also lead to
the rapid selection of compensatory mutations that di-
minish or cancel the cost of resistance [17,20,23,24].
Nonetheless, the paradigm remains that antibiotic re-
sistance is typically selected by the presence of the anti-
biotic and costly in its absence.
Here we characterize a series of mutations that confer
antibiotic resistance but appeared as beneficial mutations
in the absence of antibiotics. These mutations arose in the
context of an experiment to adapt 114 lines of E. coli to
thermal stress for 2000 generations [25]. At the end of
the experiment, we identified rifampicin resistant clones.
Surprised to find their emergence and prevalence in the
absence of antibiotics, we have explored the evolutionary
context of their appearance, along with the fitness effect of
single mutants under different environmental conditions
and genetic backgrounds. To do so, we first monitor the
trajectory of rifampicin-resistant clones within the evolu-
tion experiment, showing that the frequency trajectory
varies with the time of first appearance and other factors.
We then demonstrate that resistance is conferred by three
previously characterized variants and confirm that these
mutations confer a high level of fitness advantage under
the conditions of the evolution experiment. Finally, we
show that these same mutations can be highly deleterious
with different genetic backgrounds and environmental
conditions, thereby providing glimpses into the prevalence
of epistasis and pleiotropy for even well-characterized
mutations.
Methods
Bacterial strains and experimental design
We examined 114 replicated experimental lines from a
previous experiment [25]. The high temperature adapted
lines were founded from a common ancestral strain of
E. coli B (genotype REL1206), which was descendedfrom the strain REL606 after 2000 generations at 37°C
in Davis minimal medium supplemented with 25 μg/ml
glucose (DM25). The ancestor was evolved in 114 repli-
cate lines at 42.2°C for 2000 generations. Each line
was founded from a single colony from an asexual
clone (REL1206) that was stored at −80°C in a glycerol-
based suspension. The lines were propagated by daily
transfers of 0.1 ml of each culture into 9.9 ml of DM25,
allowing populations sizes to fluctuate daily between
5 x106 cells at the transfer bottleneck to 5 x108 cells,
for a total of ~6.64 generations of binary fission per day
[26]. Population samples of all 114 lines were taken at 100
generations, 200 generations and at 200-generation intervals
thereafter [25].
Determining the level of rifampicin resistance
To assess the level of antibiotic resistance, we estimated
the minimum inhibitory concentration (MICs) of rifam-
picin (Fisher Scientific, Fair Lawn, NJ) in the ancestral
clone and the 114 evolved clones that were characterized
genetically [25]. Each isolate was grown in 5 ml of LB
broth overnight at 37°C with constant shaking (120 rpm).
After diluting the overnight cultures down 104 into
MgSO4 (10 mM) in a 96 well microplate, we used a
multichannel pipette to deliver 2 μL of culture on the
surface of the LB agar with rifampicin. The dilution
range for rifampicin was 0–800 μg/mL (0, 0.25, 0.5, 1,
2.5, 5, 10, 25, 50, 100, 200, 400, 800). Plates were
incubated overnight at 37°C. The MIC was defined as
the lowest concentration of antibiotic inhibiting visible
growth after overnight incubation. MIC values were
confirmed in at least three separate experiments.
We constructed a histogram of the MIC distribution
of the REL1206 ancestor and the 114 evolved lines. A bi-
modal distribution is usually observed when strains have
abnormally elevated MICs, with strains distributed above
the upper end of the “susceptible” strains distribution
defined as “resistant” strains (Laboratory Standards Insti-
tute, CLSI guidelines). Using the data of the first mode
(MIC ≤ 10), a log-normal distribution was observed; a
MIC of 25 and higher was at least 2.3 standard deviations
away from the mean, justifying statistically the resistance
status of lines with MIC ≥ 25 and the susceptible status
of lines with MIC ≤ 10.
Fixation parameters and the time of appearance of
resistance
We employed mixed population samples from 200-
generation intervals to estimate the time of appearance
of the rifampicin resistant phenotype. Briefly, cultures
were inoculated from frozen stocks into 5 ml LB and
incubated overnight at 37°C. 100 μl of the culture was
diluted 106-fold and incubated on LB plates at 37°C for
12 hrs. From these plates, we randomly chose 100 colonies
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at one of three different rifampicin levels - low (12.5 μg/mL),
medium (50 μg/mL) and high (100 μg/mL) – corresponding
to lower rifampicin concentration than the MIC of the
characterized line. We incubated the rifampicin plates at
37°C for 12 hrs and estimated the frequency of resistant
individuals in the population by dividing the number of
colonies that grew in the LB + rifampicin plates by the
number (n = 100) of sampled colonies.
Based on the estimated frequency of rifampicin resist-
ance over time, we estimated three parameters of fix-
ation, as inspired by Lang et al. [27]: τup, the time at
which mutations reach 1% in the population, starting
from the beginning of the experiment; τfix, the time from
the beginning of the experiment to the time at which
mutations reach 90% in the population; and sup, the ini-
tial rate of increase of mutations (Additional file 1). sup
is a proxy for the initial selection coefficient of a rifampi-
cin resistant clone and was measured as the slope of the
linear portion between the first two observations of ri-
fampicin resistance in the populations. To estimate these
parameters we fitted a linear regression to the natural
logarithm of the ratio of resistant vs susceptible over
time using the lm function in R [28].
Strain construction and confirmation of recombinants
Single mutations that confer resistance to rifampicin were
introduced into the ancestral strain REL1206 using the
pKD46 recombineering plasmid [29]. The pkD46 plasmid
carries the lambda Red genes that support homologous
recombination. This plasmid also had temperature sen-
sitive replication and an ampicillin resistant marker, so
that it can be cured from a strain when grown at 37°C
without ampicillin. Briefly, we first introduced the pKD46
plasmid into the ancestral strain, electroporating 1 μl of
plasmid (containing between 0.5 and 1 μg of plasmid)
into 50 μl of competent cells using an Eppendorf
Electroporator 2510 set at 1.8 kV. Following electropor-
ation, we added 1 ml LB and incubated the cells at 30°C
for 2 h with shaking. We then plated 100 μl of cells on
LB agar plates containing 100 μg/ml ampicillin to select
ampicillin-resistant (ampR) transformants. The ancestral
strain carrying the pKD46 plasmid was then grown
overnight at 30°C in 5 ml of LB with 100 μg/ml of ampi-
cillin. The overnight culture was 100 fold-diluted in
100 mL of LB with ampicillin and 1 mM L-arabinose
(Sigma) and grown at 30°C to an OD600 of 0.6. We made
electrocompetent cells by washing the cultures 5 times
with ice-cold water.
We designed three oligos of 70 bp with the desired
nucleotide change in the center of the oligo (Additional
file 2: Table S1) to introduce single point mutations that
confer rifampicin resistance. 10 μM of each oligo was
electroporated into 50 μl of cells. After electroporationwe added 1 ml of LB and incubated cells at 30°C for
16 h with shaking and plated 100 μl in LB agar plates
containing rifampicin. We selected single colonies and
streaked them onto LB agar plates containing rifampi-
cin. We then incubated the purified colonies on LB
broth without antibiotic at 37°C and then tested for
ampicillin sensitivity to test for loss of the plasmid. Fi-
nally, the correct base replacement was confirmed by
Sanger sequencing of ~420 bp of the rpoB gene, which
was amplified by PCR (Additional file 2: Table S1). The
PCR thermal cycling conditions were 95°C for 4 min
followed by 30 cycles of 95°C 30 sec and 51°C 30 sec;
finally 72°C for 5 min.Measurement of relative fitness effects of rpoB mutations
The fitness of the single mutant strains relative to the
ancestral strain (A) was estimated from pairwise compe-
tition experiments following standard protocols [26].
Briefly, frozen samples of the mutated and ancestral
strains were revived in LB broth and then grown separ-
ately for one day at 37°C and a second day at 42.2°C in
DM25. The two competitors, a mutant line vs the A
(REL1206) line, were mixed at a 1:1000 volumetric ratio
and diluted 100-fold into 10 ml of DM25. We trans-
ferred 0.1 ml of each culture mixture daily into 9.9 ml of
fresh DM and incubated at 42.2°C over a duration of
two days. At the end of the daily growth cycle, we plated
100 μl of the culture on both LB agar plates and LB agar
plates supplemented with rifampicin, in order to esti-
mate the density of the total bacterial population (Arif + A)
and the resistance density strains (Arif ), respectively.
The frequency of resistant strains (freq Arif ) was estimated
as the density of Arif divided by the density of total
population. The relative fitness of the Arif mutants,
wmut, was determined from the slope of the regression =
ln [freq Arif/(1-freq Arif )] plotted against the time course
in generations [3,30].Measurements of fitness effects across genotypes and
environments
To measure the fitness effects of rifampicin resistance
mutations in different genetic backgrounds, we introduced
the rpoB mutations into two additional strains: E. coli B
REL606 and E. coli K12 MG1655. These are among the
most widely used laboratory strains and are genetically
similar, with more than 99% sequence identity over ap-
proximately 92% of their genomes. The mutants derived
form these strains were also competed against their ori-
ginal strains (REL606 and MG1655), as described above.
To test the differential effects of the mutations across
genetic backgrounds, we performed a two-way analysis
of variance (ANOVA) with genetic background (3 different
E.coli strains) and genotype (mutations) as fixed effects.
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across environments, we competed mutants against
their ancestors in four environments that differed in the
temperature of incubation and/or the composition of
the medium: 1) DM25 at 37°C, 2) DM1000 (Davis min-
imal medium supplemented with 1000 μg/ml glucose)
at 37°C, 3) DM1000 at 42.2°C and 4) LB at 42.2°C. To
test for differential fitness effects across environments,
we performed a two-way ANOVA with environment (5
environments) and genotype (3 mutations) as fixed
effects. Finally, we used a mixed-effect model to assess
the heterogeneity of fitness effects using genotype
(mutations) as a random effect and temperature (37°C
and 42.2°C) and glucose (25 μg/ml and 1000 μg/ml) as
fixed effects. Statistical analyses were performed using
the lm and lmer functions of R [28] for the two-way
ANOVAs and the mixed-effect model, respectively.
Results
Parallel mutations in the rpoB gene conferred different
levels of rifampicin resistance
We screened 114 evolved clones for the presence of ri-
fampicin resistance. These clones represented single
isolates from each of the replicate populations at the end
of the 2000 generation experiment, and all 114 clones
had been sequenced in their entirety [25]. Of these, 13
clones were resistant to rifampicin (Figure 1) at MIC
concentrations corresponding to intermediate (25 to
50 μg/ml), high (100 μg/ml) and very high (more than
800 μg/ml) level of rifampicin resistance (Table 1).
Because resistance to rifampicin has been documented
previously to be caused by single amino acid substitutions
on rpoB [18], we investigated the relationship between rpoB
mutations and resistance. Overall, 46 non-synonymous
rpoB mutations were observed in the original data set of
114 clones, but only 4 rpoB mutations were present in the
13 clones that exhibited rifampicin resistance. Three of
these four were in codon 572 of rpoB (Table 1), which hasFigure 1 MIC distribution for the high temperature adapted clones inbeen previously been shown to be both within the active
site and the location of resistance mutations [16]. Twelve of
the 13 lines had a non-synonymous mutation in codon
572, representing substitutions between Isoleucine and
either Asparagine (I572N), Leucine (I572L) or Phenyl-
alanine (I572F; Table 1). The level of resistance of these
12 clones was perfectly linked to their genotype.
Mutations I572N, I572L and I572F corresponded, re-
spectively, to an intermediate (25 to 50 μg/ml), high
(100 μg/ml) and very high (more than 800 μg/ml) level
of rifampicin resistance (Table 1). Assuming I572F is
the sole cause of resistance [18], this single mutation in
RNAP increased resistance by more than 320 fold rela-
tive to the average MIC of susceptible lines (2.5 μg/ml).
The last resistant clone had an intermediate level of
resistance and a mutation in codon 143, which is part of
the N-terminus of the β-subunit (Table 1). Mutation
R143L was found in only one clone, while each of the
three separate mutations in codon 572 were all found in
at least two clones. Since we were interested in evolu-
tionary aspects of resistance, we focused our attention
on the three mutations with a clear signal of selection –
i.e., those found to have occurred independently in
more than one line - namely mutations I572N, I572L
and I572F.
Rifampicin-resistant clones appeared early
The 12 rifampicin-resistant clones were chosen ran-
domly for sequencing from their population at the end
of the 2000-generation experiment. It was thus unclear
if rifampicin resistance was fixed in each of the 12
populations, and it was also unknown when rifampicin
resistance appeared during the experiment. To characterize
the frequency trajectory of rifampicin resistance, we
screened the 12 populations throughout 200 generation
intervals (see Methods). As detailed in Figure 2, rifampi-
cin resistance appeared before 500 generations for all
12 lines except line 77, which acquired the resistantrifampicin. The MIC of the ancestral strain is indicated with an arrow.















56 ATC→ TTC Ile (I)→ Phe (F) A1714T I572F 800 μg/mL VERY HIGH
61 ATC→ TTC Ile (I)→ Phe (F) A1714T I572F 800 μg/mL
27 ATC→ CTC Ile (I)→ Leu (L) A1714C I572L 100 μg/mL HIGH
35 ATC→ CTC Ile (I)→ Leu (L) A1714C I572L 100 μg/mL
92 ATC→ CTC Ile (I)→ Leu (L) A1714C I572L 100 μg/mL
97 ATC→ CTC Ile (I)→ Leu (L) A1714C I572L 100 μg/mL
142 ATC→ CTC Ile (I)→ Leu (L) A1714C I572L 100 μg/mL
4 ATC→ AAC Ile (I)→ Asn (N) T1715A I572N 50 μg/mL INTERMEDIATE
43 ATC→ AAC Ile (I)→ Asn (N) T1715A I572N 25 μg/mL
77 ATC→ AAC Ile (I)→ Asn (N) T1715A I572N 25 μg/mL
112 ATC→ AAC Ile (I)→ Asn (N) T1715A I572N 50 μg/mL
131 ATC→ AAC Ile (I)→ Asn (N) T1715A I572N 25 μg/mL
59 CGT→ CTT Arg (R)→ Leu (L) G428T R143L 25 μg/mL
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type was eventually fixed (f > 0.90) in 10 of the 12
populations; in contrast, resistance appeared early in
lines 56 and 131 but did not fix by generation 2000
(Figure 2).
We estimated parameters of the fixation process from
the frequency trajectory of rifampicin resistance, assumingFigure 2 Temporal dynamics of the rifampicin-resistant individuals in
numbers refer to the high temperature adapted clones in [25].that the resistance has a single origin (Additional files 1
and 3: Table S2). We observed that the time of appearance
of resistant mutations (τup) was correlated with the
speed and dynamics of fixation (Figure 3). Later-occurring
mutations (larger τup) had a smaller initial rate of increase
(sup, Figure 3A), ultimately taking longer to fix (τfix) than
early-occurring mutations (Figure 3C). For example, the12 evolved populations during 2000 generations. The line
Figure 3 Relationship between the parameters of fixation. A) The time at which mutations initially occur (τup) negatively correlates with
the initial rate of increase, Sup (P = 0.0026, Spearman’s rank correlation). B) Mutations with lower initial rate of increase (Sup) take more time to
fix (P = 0.0016, Spearman’s rank correlation). C) Late-occurring mutations (larger τup) take more time to fix (P = 0.0092, Spearman’s rank
correlation). D) No correlation found between the selective advantage measured by direct competition experiments (wmut – 1) and the initial
rate of increase (P = 0.3678 Spearman’s rank correlation). For all panels, double asterisks denote significance at P < 0.01 and ‘NS’ conveys non-
significance (P > 0.05).
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the rifampicin mutants reached a frequency higher than
0.2 at generation 200 (Figure 2) - fixed more rapidly than
lines 4, 92 and 142 (Figure 2). Not surprisingly, sup was
negatively correlated with τfix, so that lines with slower ini-
tial rate of increase of the resistance phenotype took
longer to fix the phenotype (Figure 3B).
Mutations in the rpoB gene confer both resistance and a
selective advantage
To measure the phenotype and selective advantage of rpoB
non-synonymous mutations in codon 572, we introduced
single nucleotide substitutions into the ancestral back-
ground (REL1206). With these genetic constructions we
confirmed that the single amino acid substitutions in codon
572 fully explained the level of rifampicin resistance;
that is the I572N mutation resulted in intermediate resist-
ance (25 to 50 μg/ml), with high resistance (100 μg/ml) for
I572L and the highest resistance (800 μg/ml) for I572F.
Thus, as expected [18], single base mutations in codon
572 of rpoB are sufficient to explain the rifampicin resist-
ance phenotype.
We measured the fitness effect of each of the three
mutations in competition experiments at 42.2°C in DM25.The three amino acid substitutions conferred (individu-
ally) a fitness advantage ranging from 0.182 to 0.246
(Figure 4) relative to the REL1206 ancestral line. The
selective advantage was significantly different among
mutations (P = 0.0493; ANOVA), with the pairwise dif-
ference between being significant between mutations
I572F and I572N (P =0.0398; Tukey’s). Thus, the mutations
confer resistance to rifampicin as well as a fitness advan-
tage in the absence of rifampicin at 42.2°C in DM25.
The rpoB mutations have differential effects across
genotypes and environments
Resistance mutations are usually thought to incur a cost
in the absence of antibiotic, but that is not the case for
our mutations under the conditions of the original ther-
mal stress experiment. Given the large ~20% selective
advantage of these mutations, why is rifampicin resist-
ance not fixed throughout E. coli sensu lato? Because
previous work has demonstrated a cost to rifampicin
resistance in the absence of antibiotic [19,20,31], we
suspected differential effects of the codon 572 mutations
with respect to genetic background and environmental
conditions. We thus assessed the fitness of the mutations
in different genetic backgrounds and environments.
Figure 4 Relative fitness of the rpoB mutants measured at
42.2°C in DM25 in different genetic backgrounds. The mean
relative fitness values, calculated from 6 replicates, are indicated on
top of the bars. The gray color corresponds to an advantageous
fitness effect of the mutations in relation to the ancestor and the
dark color corresponds to a deleterious fitness effect of the
mutations in relation to the ancestor. The asterisks represent
significant deviation from the null hypothesis that mean fitness
equals 1.0, with one and three asterisks denoting significance at
P < 0.05 and P < 0.001, respectively.
Table 2 Two-way analysis of variance for relative fitness
of mutants in three different genetic backgrounds
Analysis of variance
Source df SS MS F values P
Background 2 1.23909 0.61955 207.9335 <0.0001***
Genotype (Mutation) 1 0.00737 0.00737 2.4734 0.12367
Background x Genotype 2 0.01881 0.00941 3.1568 0.05334
Residuals 40 0.11918 0.00298
We treated the genetic background and the genotype (mutation) as
fixed effects.
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the three codon 572 mutations in two additional strains:
E. coli B REL606 and E.coli K12 MG1655. Both are com-
mensal E.coli laboratory strains from phylogenetic sub-
group A that were isolated a century ago. All three
mutations (I572N, I572L and I572F) conferred resistance
to rifampicin in the two new backgrounds (REL606 and
MG1655; data not shown). However, under thermal
stress (42.2°C) and low glucose (DM25) conditions in
the absence of rifampicin, the mutations had differential
fitness effects depending on genetic background. The
mutations were strongly beneficial in REL606, with a net
fitness benefit similar to that of the REL1206 back-
ground (Figure 4, Additional file 4: Table S3) but dele-
terious in the K12 background, with a ~2.5% to 10%
fitness cost in the single mutants I572L and 1572 F rela-
tive to the non-mutated K12 MG1655 competitor. In
fact, despite several attempts, we were unable to intro-
duce the I572N mutation into the MG1655 background,
suggesting that the I572N mutation may have a fitness
of zero (lethality) in the MG1655 background. Consist-
ent with these fitness observations, an analysis of vari-
ance detected a significant effect of genetic background
(Table 2). Although we did not detect a significant
background-by-mutation interaction, the low P-value
(0.053) suggests that the three mutations have differen-
tial effects across genetic backgrounds.We also assessed relative fitness for mutations in
REL1206 background for five different environments,
including two glucose treatments (DM25 and DM1000),
two temperatures (37.0°C and 42.2°C), and a different
medium (LB). These experiments revealed that fitness
effects varied across environments (Figure 5, Table 3).
The three rpoB mutations were costly at 37°C in DM25, at
37°C in DM1000 and at 42.2°C in LB medium (Additional
file 4: Table S3), but the relative fitness did not differ from
neutrality (i.e., a relative fitness that differs from 1.0) at
42.2°C in DM1000. There was also a significant non-
additive interaction between temperature and the con-
centration of glucose in DM media (Table 3); that is,
the deleterious effect on fitness of both conditions
(DM1000, 37°C) was not the sum of the deleterious
effect on fitness of each condition separately.
Discussion
The basis for our study is the observation that rifampicin
resistance arose in the absence of an antibiotic during an
evolutionary experiment. After 2000 generations of ther-
mal stress, 13 of 114 E. coli clones exhibited resistance
to rifampicin. Twelve of these 13 clones included a mu-
tation in codon 572 of the rpoB gene, with three differ-
ent mutations observed in that codon (Table 1). These
three mutations have been noted previously to confer
rifampicin resistance [32], a finding we have reconfirmed.
Moreover, each of these three mutations occurred inde-
pendently in more than one population, providing strong
evidence by the criterion of evolutionary convergence [33]
that the mutations are beneficial under the experimental
conditions. Concerning the 13th and final clone, a muta-
tion in codon 143 has been previously described to confer
low resistance to rifampicin (R143W, [34]), but the mech-
anistic causes of resistance for this clone remain unclear.
However, our analysis of the RNAP 3-D structure suggests
that codon 143 folds into the vicinity of the active (i.e.,
binding) site of the RNAP (Additional file 5). It is possible,
then, that mutations in this codon alter rifampicin bind-
ing, thus leading to resistance.
We used both direct and indirect evidence to confirm
that all three mutations in codon 572 result in a fitness
Figure 5 Relative fitness of the rpoBmutants measured in
different conditions. The mean relative fitness values are indicated in
the top of the bars. The gray color corresponds to an advantageous
fitness effect of the mutations in relation to the ancestor, the dark color
corresponds to a deleterious fitness effect of the mutations in relation
to the ancestor, and the white color corresponds to a neutral fitness
effect of the mutations in relation to the ancestor. The asterisks
represent a significant difference from a mean fitness of 1.0, based on
one-tailed t-distribution with n-1 degrees of freedom. One asterisk
represents significance at P < 0.05; two denote significance at P < 0.01;
three convey significance at P < 0.001.
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ment. For direct evidence, we introduced single mutations
into the ancestral REL1206 background and assessed
the relative fitness of mutants to unmutated REL1206.
The measured fitness effect varied statistically among
the three mutations, with relative fitnesses ranging from
1.18 to 1.25. Perhaps the most notable feature of theseTable 3 Two-way analysis of variance for relative fitness
of mutants in five different environments with the
environment and the genotype (mutants) treated as
fixed effects, and a mixed effect model with the
genotype treated as random and the temperature and
glucose treated as fixed effects
Analysis of variance
Source df SS MS F
values
P
Environment 4 1.18349 0.295871 49.0517 <0.0001***
Genotype 2 0.00386 0.001930 0.3200 0.7268
Environment x
Genotype
8 0.05311 0.006639 1.1006 0.3679





Temperature 1 49.171 <0.0001***
Glucose 1 49.333 <0.0001***
Temperature x Glucose 1 52.560 <0.0001***measurements is the magnitude of the effect. In the
experimental evolution literature, it is rare to find sin-
gle mutations with relative fitness benefits above ~15%
[35,36]. Thus, with the exception of mutations that
compensate the cost of antibiotic resistance [35], the
measured fitness benefits of the single I572N, I572L
and I572F mutations are uncommon [6,37]. We note,
however, that these high fitness values still explain only
a fraction of the total realized relative fitness benefit of
the twelve evolved clones, which have accumulated an
average of 8 mutations compared to REL1206 and an
average relative fitness increase of ~40% (mean relative
fitness 1.396; stdev 0.122) [25].
Indirect evidence for the benefit of these mutations
comes from the assessment of the frequency trajectory
of rifampicin resistance over the course of the full 2000-
generation experiment. Generally, rifampicin resistance
evolved early – within 500 generations - and swept to
fixation within a few hundred generations (Figure 2).
This steep increase in frequency is consistent with a high
selection coefficient for the haplotypes that carry the
resistance marker. We have measured the selection co-
efficient for these haplotypes by estimating sup, which
ranges between 0.015 and 0.077 (Figure 3A, Additional
file 3: Table S2). While these are high selection coefficients,
they are not directly comparable to our relative fitness
estimates, for several reasons (see below). What sup does,
however, is confirm that the capability for antibiotic
resistance may be highly beneficial even in the absence
of antibiotic.Fixation dynamics of the resistance mutations
The frequency trajectories also provide crucial insights
into the fixation dynamics of beneficial mutations. One
interesting observation is that the relative fitnesses of
single rifR mutations do not correlate with the estimated
selective coefficient (sup) of the populations that harbor
these mutations (Figure 3D). This may reflect a lack
statistical power to detect a correlation - since there
are only three relative fitness measures – or may reflect
the possibility that the resistant individuals observed at
intermediate time points harbor different resistant
mutations than the one observed at the end of the experi-
ment. Nonetheless, we believe the lack of a relationship is
meaningful. For example, the I572F rifampicin-resistant
mutation found in lines 56 and 61 has the highest rela-
tive fitness as a single mutation (Figure 5), but rifampi-
cin resistance was not fixed rapidly in these two lines.
Instead, we find that early-occurring rifR mutations take
less time to reach fixation than late-occurring mutations
(Figure 3C); this pattern suggests either that epistasis,
clonal interference or frequency dependent fitness
interactions influences sup [27].
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returns epistasis is expected theoretically [4] and has been
observed empirically as more and more mutations accu-
mulate over the time-course of an experiment [6,37].
Under diminishing-returns, a relatively late occurring rpoB
mutation may have a smaller fitness effect, conditional on
the occurrence of previous beneficial mutations. For clonal
interference, competition between beneficial haplotypes
will slow the process of fixation [38,39]. Finally, complex
dynamics such as those observed in lines 56 and 131
might be due to frequency-dependent selection. In any
case, such competition may be more common in the later
stages of an experiment when multiple mutations have
accrued [38]. In contrast, early rifR mutations likely oc-
curred in a REL1206 background that was fairly devoid
of other new mutations, thus minimizing possibilities
for either clonal interference or epistatic interactions
with other new mutations.
The possibility that frequency trajectories have been
shaped in part by epistasis (whether as diminishing-
returns or one of several other possible forms [40]) is
not surprising given the study of Tenaillon et al. [25].
This study detected statistical associations among muta-
tions that were consistent with extensive and varied epi-
static effects. These associations shaped the adaptive
response to thermal stress into one of two distinct gen-
etic solutions typified by mutations either in rpoB or in
the termination factor rho, but rarely in both genes. To
investigate the potential relationship of sup to these stat-
istical associations, we examined genetic data from
Tenaillon et al. [25]. Clones from lines 43, 61 and 131,
all of which had high τfix values (> 400 generations;
Figure 2) carried mutations in both rho and rpoB, a
combination statistically highly disfavored among the
full dataset of 114 clones. This observation suggests that
the long fixation time in these lines could be due in part
to negative epistatic interactions between rho and rpoB
mutations that reduces beneficial effects of both mutations.
The strength and mechanism of these interactions need
to be characterized more fully, however.
Previous studies have identified potential epistatic inter-
actions with mutations in codon 572 [41], and epistasis
must contribute to varying fitness effects among our gen-
etic backgrounds (Figure 4). In the high temperature and
low glucose condition, our three codon 572 mutations
conferred a slightly (but not significantly) higher relative
fitnesses in the REL606 background than in the ances-
tral REL1206 background. The similar effects in these
two backgrounds may not be surprising, however, given
that REL1206 and REL606 differ by only a handful of
mutations: REL1206 differs from REL606 in 3 SNPs,
an IS element and a large deletion [25,42]. In contrast,
the rifR mutations are detrimental in the K12 MG1655
background (Table 2), even though K12 and B aregenetically similar (> 99% sequence identity over ~92%
of their genomes [43]).
The specificity of adaptation
The effects of the rifampicin resistance mutations also
vary as a function of environment. In our study, the only
environment in which the mutations are demonstrably
beneficial is that of the original evolution experiment
(high temperature and low glucose). In contrast, the
effects of rifR mutations are indistinguishable from
neutrality in a high temperature and rich glucose envir-
onment and demonstrably detrimental at 37°C in poor
and rich glucose environment [19,20,31] (Figure 5,
Additional file 4: Table S3).
With the exception of lethal selection or niche creation
[11] experiments, most other studies have demonstrated
that the fitness advantage conferred by a mutation is
maintained across environments and conditions [9,10].
In other words, they have found that beneficial mutations
are generally not severely compromised in other environ-
ments [10]. The logical extension of these observations is
that a single beneficial mutation is unlikely to result in
niche specialization, because it will not lead to drastic
fitness differences across environments.
In stark contrast to these studies, we do observe the
potential for the evolution of ecological specialization in
a single mutational step, because all three mutations in
codon 572 of rpoB confer a selective advantage in the
conditions of the original evolution experiment but sig-
nificant disadvantages in other environments (Table 3)
and genetic backgrounds (Table 2). In this context, it
is important to repeat that this potential for niche
specialization is not a function of antibiotic resistance,
for which niche specialization is well known, but rather
due to fitness effects across antibiotic-free environments.
The question remains as to whether our single rpoB
mutations are rare or instead cast doubt on previous
conclusions that niche specialization is “. . . unlikely to
occur through the substitution of a single mutation”
[10]. The degree of ecological specialization for our
single mutations could be due in part to the drastic
selection pressure (high temperature) in the original
experiment or to rpoB itself. Because mutations within
rpoB can be highly pleiotropic, they can affect a series
of downstream traits like gene expression [44,45] that
may be fine-tuned for specific selective regimes. We
note that highly pleiotropic (but non-rpoB) mutations
have been observed in early stages of adaptation to
ethanol stress [46] and glycerol minimal media [47],
suggesting that early mutations in adaptation are com-
monly involved in transcriptional regulation with large
fitness and pleiotropic effects [48,49]. As such, our rpoB
mutations may not be uncommon, either in their effects
or in their potential for ecological specialization. Thus, in
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specialization by single beneficial mutations is still an open
question worthy of further study.Mechanism
Several experimental evolution studies have shown the
fixation of mutations in RNAP during stress adaptation
[44,45]. This suggests that modifications in the RNAP
could be a general mechanism for adaptation to new
environments. Yet, the mechanistic basis for the beneficial
effect of rpoB mutations at high temperature remains
unclear. Since temperature affects the stability and activity
of proteins [50-52], rpoB mutations may modify the stabil-
ity and/or activity of RNAP at high temperatures. For
example, previous studies have shown that mutation
I572F increase transcription termination [53], and mu-
tation I572L reduces transcription efficiency at 37°C
[19]. Another (but not mutually-exclusive) hypothesis is
that rpoB mutations cause changes in gene expression
through the redistribution of RNAP in manner that
favors adaptation to new environments [44]. The unique
challenge here is explaining how these mechanistic
effects can be advantageous in REL1206 but (for ex-
ample) disadvantageous in K12 (Figure 4). Fortunately,
questions of mechanism are amenable to future experi-
mental investigation.Conclusions
Numerous studies have investigated rifampicin resist-
ance in bacterial populations. The general tenor of these
studies is that rifampicin resistance is deleterious in the
absence of an antibiotic, and thus compensatory mutations
are required for resistance to persist (e.g. [20]). Our study
differs from most previous in demonstrating the origin of
resistance in the absence of antibiotics and also in demon-
strating that the resistance mutations can be highly benefi-
cial in the absence of antibiotic, depending on both the
background of the mutation and the environment.Additional files
Additional file 1: Parameters of fixation.
Additional file 2: Table S1. Oligonucleotides and primers used in this
study.
Additional file 3: Table S2. Parameters of fixation estimated from the
frequency trajectories.
Additional file 4: Table S3. Relative fitness measured in different
conditions and different genetic backgrounds.
Additional file 5: Three-dimensional structure of RNAP generated
using Jmol from the Protein Data Bank (www.rcsb.org).Competing interests
The authors declare that they have no competing interests.Authors’ contributions
AR-V helped designing the study, performed the experiments and analyses.
BG participated in the design of the study and in the analysis of data. OT
conceived and designed the study. All authors participated in writing the
paper and they all approved the final manuscript.Acknowledgments
This work was supported by NSF grant DEB-0748903 and by Agence
Nationale de la Recherche, Programme Génomique, grant ANR-08-GENM-
023-001 and UC MEXUS-CONACYT Doctoral Fellowship a doctoral fellowship
to AR-V. We thank Pamela McDonald and Rebecca Gaut for assistance in the
laboratory.
Author details
1Department of Ecology and Evolutionary Biology, UC Irvine, Irvine, CA, USA.
2INSERM, Université Paris7, Faculté de Médicine Denis Diderot, UMR-S 722,
Paris, France. 3INSERM UMR-S 722, Université Paris7, Faculté de Médicine
Denis Diderot, Site Xavier Bichat, 16 rue Henri Huchard, 75018, Paris, France.
Received: 6 November 2012 Accepted: 11 January 2013
Published: 22 February 2013References
1. Orr HA: The genetic theory of adaptation: A brief history. Nat Rev Genet
2005, 6:119–127.
2. Kimura M: The neutral theory of molecular evolution. Cambridge: Cambridge
University Press; 1983.
3. Schrag SJ, Perrot V, Levin BR: Adaptation to the fitness costs of antibiotic
resistance in Escherichia coli. Proc R Soc Lond B 1997, 264:1287–1291.
4. Weinreich DM, Watson RA, Chao L: Perspective: Sign epistasis and genetic
constraint on evolutionary trajectories. Evolution 2005, 59:1165–1174.
5. Gros PA, Le Nagard H, Tenaillon O: The Evolution of epistasis and its links
with genetic robustness, complexity and drift in a phenotypic model of
adaptation. Genetics 2009, 182:277–293.
6. Khan AI, Dinh DM, Schneider D, Lenski RE, Cooper TF: Negative epistasis
between beneficial mutations in an evolving bacterial population.
Science 2011, 332:1193–1196.
7. Woods RJ, Barrick JE, Cooper TF, Shrestha U, Kauth MR, Lenski RE: Second-
order selection for evolvability in a large Escherichia coli population.
Science 2011, 331:1433–1436.
8. Remold SK, Lenski RE: Contribution of individual random mutations to
genotype-by-environment interactions in Escherichia coli. Proc Natl Acad
Sci USA 2001, 98:11388–11393.
9. Ostrowski EA, Rozen DE, Lenski RE: Pleiotropic effects of beneficial
mutations in Escherichia coli. Evolution 2005, 59:2343–2352.
10. Bataillon T, Zhang TY, Kassen R: Cost of adaptation and fitness effects of
beneficial mutations in Pseudomonas fluorescens. Genetics 2011,
189:939–949.
11. MacLean RC, Bell G, Rainey PB: The evolution of a pleiotropic fitness
tradeoff in Pseudomonas fluorescens. Proc Natl Acad Sci USA 2004,
101:8072–8077.
12. Taubes G: The bacteria fight back. Science 2008, 321:356–361.
13. Andersson DI, Levin BR: The biological cost of antibiotic resistance. Curr
Opin Microbiol 1999, 2:489–493.
14. MacLean RC, Hall AR, Perron GG, Buckling A: The population genetics of
antibiotic resistance: integrating molecular mechanisms and treatment
contexts. Nat Rev Genet 2010, 11:405–414.
15. Marcusson LL, Frimodt-Moller N, Hughes D: Interplay in the selection of
fluoroquinolone resistance and bacterial fitness. PLoS Pathog 2009,
5:1553–7366.
16. Tupin A, Gualtieri M, Roquet-Baneres F, Morichaud Z, Brodolin K, Leonetti JP:
Resistance to rifampicin: at the crossroads between ecological, genomic
and medical concerns. Int J Antimicrob Agents 2010, 35:519–523.
17. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J,
Niemann S, Gagneux S: Whole-genome sequencing of rifampicin-resistant
Mycobacterium tuberculosis strains identifies compensatory mutations in
RNA polymerase genes. Nat Genet 2012, 44:106–110.
18. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst
SA: Structural mechanism for rifampicin inhibition of bacterial RNA
polymerase. Cell 2001, 104:901–912.
Rodríguez-Verdugo et al. BMC Evolutionary Biology 2013, 13:50 Page 11 of 11
http://www.biomedcentral.com/1471-2148/13/5019. Reynolds MG: Compensatory evolution in rifampin-resistant Escherichia
coli. Genetics 2000, 156:1471–1481.
20. Brandis G, Wrande M, Liljas L, Hughes D: Fitness-compensatory mutations
in rifampicin-resistant RNA polymerase. Mol Microbiol 2012, 85:142–151.
21. Kassen R, Bataillon T: Distribution of fitness effects among beneficial
mutations before selection in experimental populations of bacteria. Nat
Genet 2006, 38:484–488.
22. Trindade S, Sousa A, Gordo I: Antibiotic resistance and stress in the light
of fisher’s model. Evolution 2012, 66:3815–3824.
23. Levin BR, Perrot V, Walker N: Compensatory mutations, antibiotic
resistance and the population genetics of adaptive evolution in bacteria.
Genetics 2000, 154:985–997.
24. Hall AR, MacLean RC: Epistasis buffers the fitness effect of rifampicin-
resistance mutations in Pseudomonas aeruginosa. Evolution 2011,
65:2370–2379.
25. Tenaillon O, Rodriguez-Verdugo A, Gaut RL, McDonald P, Bennett AF, Long
AD, Gaut BS: The molecular diversity of adaptive convergence. Science
2012, 335:457–461.
26. Lenski RE, Rose MR, Rose MR: Long-term experimental evolution in
Escherichia coli. I. Adaptation and divergence during 2,000 generations.
Am Nat 1991, 138:1315–1341.
27. Lang GI, Botstein D, Desai MM: Genetic variation and the fate of beneficial
mutations in asexual populations. Genetics 2011, 188:647–661.
28. R: A language and environment for statistical computing. http://www.R-project.org/.
29. Datsenko KA, Wanner BL: One-step inactivation of chromosomal genes in
Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 2000,
97:6640–6645.
30. Lenski RE: Quantifying fitness and gene stability in microorganisms. In
Assessing ecological risks of biotechnology. Edited by Ginzburg LR. Boston:
Butterworth-Heinemann; 1991:173–192.
31. Barrick JE, Kauth MR, Strelioff CC, Lenski RE: Escherichia coli rpoB mutants
have increased evolvability in proportion to their fitness defects. Mol Biol
Evol 2010, 27:1338–1347.
32. Garibyan L, Huang T, Kim M, Wolff E, Nguyen A, Nguyen T, Diep A, Hu KB,
Iverson A, Yang HJ, Miller JH: Use of the rpoB gene to determine the
specificity of base substitution mutations on the Escherichia coli
chromosome. DNA Repair 2003, 2:593–608.
33. Christin PA, Weinreich DM, Besnard G: Causes and evolutionary
significance of genetic convergence. Trends Genet 2010, 26:400–405.
34. Severinov K, Soushko M, Goldfarb A, Nikiforov V: RifR mutations in the
beginning of the Escherichia coli rpoB gene. Mol Gen Genet 1994, 244:120–126.
35. Maisnier-Patin S, Berg OG, Liljas L, Andersson DI: Compensatory adaptation
to the deleterious effect of antibiotic resistance in Salmonella
typhimurium. Mol Microbiol 2002, 46:355–366.
36. Rozen DE, de Visser JA, Gerrish PJ: Fitness effects of fixed beneficial
mutations in microbial populations. Curr Biol 2002, 12:1040–1045.
37. Chou HH, Chiu HC, Delaney NF, Segre D, Marx CJ: Diminishing returns
epistasis among beneficial mutations decelerates adaptation. Science
2011, 332:1190–1192.
38. Gerrish PJ, Lenski RE: The fate of competing beneficial mutations in an
asexual population. Genetica 1998, 102–3:127–144.
39. de Visser JA, Rozen DE: Clonal interference and the periodic selection of
new beneficial mutations in Escherichia coli. Genetics 2006, 172:2093–2100.
40. Phillips PC: Epistasis - the essential role of gene interactions in the structure
and evolution of genetic systems. Nat Rev Genet 2008, 9:855–867.
41. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, Gordo I: Positive
epistasis drives the acquisition of multidrug resistance. PLoS Genet 2009,
5:e1000578.
42. Barrick JE, Yu DS, Yoon SH, Jeong H, Oh TK, Schneider D, Lenski RE, Kim JF:
Genome evolution and adaptation in a long-term experiment with
Escherichia coli. Nature 2009, 461:1243–1274.
43. Studier FW, Daegelen P, Lenski RE, Maslov S, Kim JF: Understanding the
differences between genome sequences of Escherichia coli B strains
REL606 and BL21(DE3) and comparison of the E-coli B and K-12
genomes. J Mol Biol 2009, 394:653–680.
44. Conrad TM, Frazier M, Joyce AR, Cho BK, Knight EM, Lewis NE, Landick R,
Palsson BO: RNA polymerase mutants found through adaptive evolution
reprogram Escherichia coli for optimal growth in minimal media. Proc
Natl Acad Sci USA 2010, 107:20500–20505.45. Freddolino PL, Goodarzi H, Tavazoie S: Fitness landscape transformation
through a single amino acid change in the Rho terminator. PLoS Genet
2012, 8:e1002744.
46. Goodarzi H, Hottes AK, Tavazoie S: Global discovery of adaptive
mutations. Nat Methods 2009, 6:581–583.
47. Applebee MK, Herrgard MJ, Palsson BO: Impact of individual mutations on
increased fitness in adaptively evolved strains of Escherichia coli.
J Bacteriol 2008, 190:5087–5094.
48. Fong SS, Joyce AR, Palsson BO: Parallel adaptive evolution cultures of
Escherichia coli lead to convergent growth phenotypes with different
gene expression states. Genome Res 2005, 15:1365–1372.
49. Hindre T, Knibbe C, Beslon G, Schneider D: New insights into bacterial
adaptation through in vivo and in silico experimental evolution. Nat Rev
Microbiol 2012, 10:352–365.
50. Singleton R Jr, Amelunxen RE: Protein from thermophilic microorganisms.
Bacteriol Rev 1973, 37:320–342.
51. Ryals J, Little R, Bremer H: Temperature dependence of RNA synthesis
parameters in Escherichia coli. J Bacteriol 1982, 151:879–887.
52. Mejia YX, Mao HB, Forde NR, Bustamante C: Thermal probing of E.coli RNA
polymerase off-pathway mechanisms. J Mol Biol 2008, 382:628–637.
53. Jin DJ, Walter WA, Gross CA: Characterization of the termination
phenotype of rifampicin-resistant mutants. J Mol Biol 1988, 202:245–253.
doi:10.1186/1471-2148-13-50
Cite this article as: Rodríguez-Verdugo et al.: Evolution of Escherichia coli
rifampicin resistance in an antibiotic-free environment during
thermal stress. BMC Evolutionary Biology 2013 13:50.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
